Skip to main content
. 2015 Nov 14;13:317. doi: 10.1186/s12957-015-0730-3

Fig. 1.

Fig. 1

RBM3 immunoexpression and H&E morphology in benign urothelium (a), urothelial carcinoma in situ (b), primary invasive urothelial carcinoma (c), and matched metastatic urothelial carcinoma (d)